Viridian Therapeutics, Inc.
VRDN· Nasdaq
VRDNViridian Therapeutics, Inc.
Filed Mar 15, 2018 · 10-K · 74 days after period end · 0001590750-18-000006
| Metric | Q4 2017 | Q4 2016 | Q4 2015dderived from reported figures | Q4 2014dderived from reported figures |
|---|---|---|---|---|
| Revenue | $1.19M | $509.00K | $1.60M | $1.51M |
| Net Income | -$6.39M | -$5.97M | -$2.98M | -$2.26M |
| EPS Diluted | -$0.29 | -$9.20 | — | — |
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2017 · filed Mar 15, 2018 · 74 d after period end
